2022
DOI: 10.1097/coh.0000000000000723
|View full text |Cite
|
Sign up to set email alerts
|

Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV

Abstract: Purpose of reviewThis paper provides a critical review of recent therapeutic advances in long-acting (LA) modalities for human immunodeficiency virus (HIV) treatment and prevention. Recent findingsLA injectable antiretroviral therapy (ART) has been approved in the United States, Canada and Europe; the United States also has approved LA injectable preexposure prophylaxis (PrEP) and the World Health Organization has recommended the vaginal PrEP ring. Current LA PrEP modalities in clinical trials include injectio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 23 publications
(17 citation statements)
references
References 82 publications
0
17
0
Order By: Relevance
“…There is therefore a need to ensure that the ongoing and future rollout of long-acting and other PrEP modalities is equitable globally while also ensuring the continued rollout of oral PrEP. 15 …”
Section: Discussionmentioning
confidence: 99%
“…There is therefore a need to ensure that the ongoing and future rollout of long-acting and other PrEP modalities is equitable globally while also ensuring the continued rollout of oral PrEP. 15 …”
Section: Discussionmentioning
confidence: 99%
“…The population level, ‘successful’ rollout of PrEP in Australia may give the impression that taking PrEP is easy, desirable, reasonable and sustainable—and it may well be for many people who continue to use it (Kirby Institute, 2022). At the same time, the international field is looking towards ‘long‐acting’ forms of PrEP, including injectable and implantable pharmaceutical agents that last several months at a time (Philbin & Perez‐Brumer, 2022). It may be tempting to consider that these new clinical interventions may provide a solution to the everyday mess of taking pills, partly because these agents are likely to be administered in the clinic rather than in the household.…”
Section: Discussionmentioning
confidence: 99%
“…However, real-world experience using LAI-CAB/RPV has illuminated the value in engaging patients in informed risk-benefits discussion about this therapeutic opportunity and the need for dedicated resources to support the implementation of this novel treatment so that access can be streamlined, supported, and equitable. Substantial and sustained investment in developing infrastructural support, including personnel, is needed to facilitate access and delivery of LAI-ART for a broad range of PWH across a variety of settings as to not widen existing disparities in HIV care [ 19 , 20 ].…”
Section: Discussionmentioning
confidence: 99%